To amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.
Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.
Message on House action received in Senate and at desk: House amendments to Senate amendment.
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Introduced in House
Introduced in House
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Referred to the House Committee on the Judiciary.
Subcommittee on Antitrust, Commercial, and Administrative Law Discharged.
Committee Consideration and Mark-up Session Held.
Ordered to be Reported.
Reported by the Committee on Judiciary. H. Rept. 116-695.
Reported by the Committee on Judiciary. H. Rept. 116-695.
Placed on the Union Calendar, Calendar No. 578.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line